FINNENCE ▪ THE WIRE FILE
THE WIRE · № 67650
News■ Unclear/unknown
Cambridge Heartwear Awarded £184 Million NHS Tender for World's First Medical-Grade, Wirelessly Charged, Reusable ECG Wearable
KINDNews
DIRECTION■ Unclear/unknown
SOURCES2
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-10-06 16:55 UTC
LAST UPDATE2026-10-06 17:00 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
An NHS tender win for a private UK medtech firm is notable but the company is not listed among covered tickers.
Medtech contract win, no public ticker
CATALYST TO WATCH
Future NHS orders or company listing
MAIN RISK
Tender execution and reimbursement delays
FULL DISPATCH
CAMBRIDGE, England, Oct. 6, 2026 /PRNewswire/ -- Cambridge Heartwear® Limited (www.camheartwear.com) has secured a landmark £184 million tender with the National Health Service (NHS) of the UK for HeartSense®, the world's first medical-grade, multi-channel, portable, wirelessly charged...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
2 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
New Phase 3 trial: J-LINX: Japan LINerixibat eXtension Study — GlaxoSmithKline2026-10-06 12:00 UTC
New Phase 3 trial: J-LINX: Japan LINerixibat eXtension Study — GlaxoSmithKline2026-10-06 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity — Novo Nordisk A/S2026-10-06 12:00 UTC
New Phase 3 trial: A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity — Novo Nordisk A/S2026-10-06 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: Phase 3 Evaluation of Sovateltide for the Treatment of Acute Traumatic Brain Injury — Pharmazz, Inc.2026-10-06 12:00 UTC
New Phase 3 trial: Phase 3 Evaluation of Sovateltide for the Treatment of Acute Traumatic Brain Injury — Pharmazz, Inc.2026-10-06 12:00 UTC
→CORRELATIONshares Healthcare
Phase 3 results posted: A Study Testing the Use of a Perivascular Sirolimus Formulation (Sirogen) in ESRD Patients Undergoing AV Fistula Surgery — Vascular Therapies, Inc.2026-10-06 12:00 UTC
Phase 3 results posted: A Study Testing the Use of a Perivascular Sirolimus Formulation (Sirogen) in ESRD Patients Undergoing AV Fistula Surgery — Vascular Therapies, Inc.2026-10-06 12:00 UTC
→CORRELATIONshares Healthcare
Phase 3 results posted: A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) — Janssen Research & Development, LLC2026-10-06 12:00 UTC
Phase 3 results posted: A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) — Janssen Research & Development, LLC2026-10-06 12:00 UTC
→CORRELATIONshares Healthcare
Johnson & Johnson CEO on Why He’s Not Focusing on GLP-1s2026-10-06 17:13 UTC
Johnson & Johnson CEO on Why He’s Not Focusing on GLP-1s2026-10-06 17:13 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.